Tenofovir Disoproxil Fumarate (TDF) 300mg 3 Years RD Therapy Chinese Chronic Hepatitis B (CHN) CHB Multiple Nucleos(t)Ide Analogues (NAs) Failure Points Pts PH4 PMS Study

Exclusion Criteria

• •Hepatocellular carcinoma as evidenced by one of the following: Suspicious foci on ultrasound or radiological examination, Normal ultrasound but a history of rising serum alpha-fetoprotein and serum alpha-fetoprotein \>20 nanogram (ng) per mL at screening.
• •Clinical signs of decompensated liver disease at baseline. These may include but are not limited to:Total serum bilirubin \>1.5 x Upper limit of the normal range (ULN), International Normalized Ratio \>1.3, Serum albumin \<32grams per Liter (g/L), History of clinical hepatic decompensation (e.g., ascites, variceal bleeding, or encephalopathy).
• •Creatinine clearance less than 70 milliliter per minutes (mL/min).
• •Alanine aminotransferase \>10 times ULN at screening or history of acute exacerbation leading to transient decompensation.
• •Haemoglobin \<8 grams per deciliter (g/dL), absolute neutrophil count \<1.0 x 10\^9 per Liter, platelets \<75 x 10\^9 per Liter.
• •Evidence of active liver disease due to autoimmune hepatitis (antinuclear antibody titre \>1:160)
• •Any serious or active medical or psychiatric illnesses other than hepatitis B which, in the opinion of the Investigator, would interfere with subject treatment, assessment or compliance with the protocol. This would include any uncontrolled clinically significant renal, cardiac, pulmonary, vascular, neurogenic, digestive, metabolic (diabetes, thyroid disorders, adrenal disease), immunodeficiency disorders, pathological fractures or cancer.
• •Active alcohol or drug abuse or history of alcohol or drug abuse considered by the Investigator to be sufficient to hinder compliance with treatment, participation in the study or interpretation of results.
• •A female who is breastfeeding or plan to breast.
• •Use of immunosuppressive therapy, immunomodulatory therapy \[including Pegylated interferon (PEG-IFN) and short-acting interferon or thymosin alpha\], systemic cytotoxic agents within the previous 6 months prior to screening.
• •Planned for liver transplantation or previous liver transplantation.
• •Receipt of TDF within 6 months prior to screening.
• •Therapy with nephrotoxic drugs (e.g., aminoglycosides, amphotercin B, vancomycin, cidofovir, foscarnet, cis-platinum, pentamidine etc.) or competitors of renal excretion (e.g., probenecid) within 2 months prior to study screening or the expectation that subject will receive any of these during the course of the study.
• •History of hypersensitivity to nucleoside and/or nucleotide analogues and/or any component of study medication.
• •Inability to comply with study requirements as determined by the study Investigator.